3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Neoplasm Metastasis
10
Carcinoma, Medullary
10
Thyroid Neoplasms
5
Lung Neoplasms
5
Prostatic Neoplasms
3
Neoplasms
3
Adenocarcinoma
3
Familial medullary thyroid carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Biliary Tract Neoplasms
1
Aggression
1
Advanced Breast Cancer
1
Interventions
Gemcitabine
27
Cisplatin
24
pembrolizumab
15
durvalumab
12
Fluorouracil
11
Capecitabine
10
Oxaliplatin
9
Leucovorin
8
Bevacizumab
7
Carboplatin
5
Paclitaxel
4
Nivolumab
4
Irinotecan
4
Injections
4
zanidatamab
3
trametinib
3
lenvatinib
3
derazantinib
3
atezolizumab
3
Ramucirumab
3
Docetaxel
3
tremelimumab
2
surufatinib
2
pertuzumab
2
gemcitabine-oxaliplatin regimen
2
envafolimab
2
Trastuzumab
2
S 1 (combination)
2
Itraconazole
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biliary Tract Neoplasms
×
vandetanib
×
Clear all
NCT00753675
2016-10-10
VANGOGH
Sanofi
Phase 2
Completed
174 enrolled
12 charts